(NPR) — An expert panel has issued a new recommendation saying people at high risk of HIV infection should be offered PrEP, taken in a daily pill.
The move could be influential in expanding coverage of the drug, which can reduce risk of infection by up to 92%.
The U.S. Preventive Services Task Force says people at high risk of being infected with HIV should be offered a daily pill containing antiretroviral medications. The drug's cost remains a hurdle.
There's lots of evidence that preexposure prophylaxis — also known as PrEP — is effective. The Food and Drug Administration-approved pill Truvada contains two antiretroviral medicines (tenofovir and emtricitabine).
The Centers for Disease Control and Prevention cites evidence that PrEP can reduce the risk of HIV infection by up to 92% in people who are at high risk and who take the drug consistently.
The CDC recommended PrEP several years ago and calls it “a powerful HIV prevention tool,” but so far uptake of PrEP has been slow.